Perpetua Medical (PERP) Q4 2024 earnings summary

Executive summary

• Transitioned to a focused acquisition strategy, divesting non-core assets and acquiring ES-Medical AB, which contributed significantly to Q4 revenue.

• ES-Medical secured a major order from Karolinska University Hospital, highlighting operational progress.

• Strong cash position at year-end, supported by disciplined cost reductions and limited use of loan facilities.

Financial highlights

• Q4 net revenue rose 62% year-over-year to 4,164 KSEK, mainly from ES-Medical; full-year revenue fell 30% to 6,939 KSEK due to divestments.

• Q4 operating loss improved to -1,105 KSEK from -4,159 KSEK; full-year operating loss narrowed to -2,456 KSEK from -18,492 KSEK.

• Q4 EPS was -0.28 SEK (vs. -1.46 SEK); full-year EPS was -0.56 SEK (vs. -10.56 SEK).

• Year-end cash balance was 9,400 KSEK, up from 5,533 KSEK; full-year cash flow was 3,867 KSEK.

• Realization gain of 6,330 KSEK from Druglog divestment supported results.

Outlook and guidance

• Cost savings expected to reach full effect from Q1 2025.

• Focus remains on achieving positive cash flow, establishing long-term financing, and building a world-class acquisition platform.